Skip to main content

Table 6 Comparison between HFNCO group and NIV group 24 h post treatment, as regards vital signs, arterial blood gases, and outcomes

From: High flow nasal cannula oxygen and non-invasive mechanical ventilation in management of COVID-19 patients with acute respiratory failure: a retrospective observational study

 

HFNCO (n=37)

NIV (n=26)

P

Heart rate (beats/minute)

85.29 ± 8.69

84.92 ± 6.42

0.42

Respiratory rate (breaths/minute)

21.48 ± 2.11

23.76 ± 3.58

<0.01*

Mean arterial blood pressure (mmHg)

89.29 ± 4.96

89.42 ± 3.91

0.45

PH

7.41 ± 0.03

7.43 ± 0.02

0.06

PaCO2 (mmHg)

38.32 ± 4.32

38.15 ± 3.72

0.44

PaO2/FiO2

225.67 ± 44.33

241.53 ± 49.43

0.09

Duration of treatment (days)

5.53 ± 1.11

5.86 ± 1.10

0.43

Success rate %

86.4%

84.61 %

0.24

Intubation rate %

10.81 %

11.53 %

0.34

Mortality rate %

2.7 %

3.8 %

0.32

  1. HFNCO high flow nasal cannula oxygen, NIV non-invasive ventilation, PaCO2 arterial pressure of carbon dioxide, PaO2 arterial pressure of oxygen, FiO2 fraction of inspired oxygen
  2. Significance at *P<0.05